59 related articles for article (PubMed ID: 12889482)
1. Nucleoside-free regimen tested.
AIDS Patient Care STDS; 2003 Jun; 17(6):309-10. PubMed ID: 12889482
[No Abstract] [Full Text] [Related]
2. Anti-HIV agents. Efavirenz versus indinavir: who really wins?
TreatmentUpdate; 2000 Feb; 12(1):4-5. PubMed ID: 12125628
[No Abstract] [Full Text] [Related]
3. Treating advanced HIV infection.
Boffito M; Bonora S; Sinicco A; Raiteri R; Milia MG; Khoo SH; Hoggard PG; Back DJ; Di Perri G
J Acquir Immune Defic Syndr; 2003 Nov; 34(3):344-5. PubMed ID: 14600582
[No Abstract] [Full Text] [Related]
4. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
[TBL] [Abstract][Full Text] [Related]
5. Using ritonavir with indinavir in cases of virologic failure.
TreatmentUpdate; 2001; 12(12):7. PubMed ID: 11570095
[No Abstract] [Full Text] [Related]
6. DMP 266 and indinavir combination.
AIDS Patient Care STDS; 1997 Aug; 11(4):287-8. PubMed ID: 11361845
[No Abstract] [Full Text] [Related]
7. Efavirenz in HIV infection.
Casado JL; Moreno S
N Engl J Med; 2000 Apr; 342(17):1290-1. PubMed ID: 10787332
[No Abstract] [Full Text] [Related]
8. Maintenance of successful ritonavir-boosted indinavir and efavirenz therapy in an HIV-infected patient with tuberculosis.
Boyd MA; Burger DM; Phanuphak P; Cooper DA
AIDS; 2006 Apr; 20(7):1083-5. PubMed ID: 16603870
[No Abstract] [Full Text] [Related]
9. [5 years' data are convincing. Lopinavir as primary therapy is effective and safe in the long term].
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():92. PubMed ID: 15373069
[No Abstract] [Full Text] [Related]
10. Switching from protease inhibitors to the non-nuke efavirenz.
TreatmentUpdate; 2001; 12(12):3. PubMed ID: 11570089
[No Abstract] [Full Text] [Related]
11. Efficacy and safety of an anti-retroviral combination regimen including either efavirenz or lopinavir-ritonavir with a backbone of two nucleoside reverse transcriptase inhibitors.
Panagopoulos P; Tsiodras S; Antoniadou A; Katsarolis I; Papadopoulos A; Poulakou G; Giamarellou H
Clin Microbiol Infect; 2006 May; 12(5):486-9. PubMed ID: 16643529
[TBL] [Abstract][Full Text] [Related]
12. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.
Staszewski S; Morales-Ramirez J; Tashima KT; Rachlis A; Skiest D; Stanford J; Stryker R; Johnson P; Labriola DF; Farina D; Manion DJ; Ruiz NM
N Engl J Med; 1999 Dec; 341(25):1865-73. PubMed ID: 10601505
[TBL] [Abstract][Full Text] [Related]
13. Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009.
Boyd MA; Siangphoe U; Ruxrungtham K; Duncombe CJ; Stek M; Lange JM; Cooper DA; Phanuphak P
HIV Med; 2005 Nov; 6(6):410-20. PubMed ID: 16268823
[TBL] [Abstract][Full Text] [Related]
14. [Long-term immunologic response in HIV-infected patients with CD4 cell counts Le Moing V; Eid Z; Ecobichon JL; Duval X; Longuet P; Elbim C; Brun-Vezinet F; Leport C; Vilde JL
Ann Med Interne (Paris); 2001 Feb; 152(1):11-4. PubMed ID: 11240420
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality of life in HIV patients switching to twice-daily indinavir/ritonavir regimen or continuing with three-times-daily indinavir-based therapy.
Badía X; Podzamczer D; Moral I; Roset M; Arnaiz JA; Loncà M; Casiró A; Rosón B; Gatell JM;
Antivir Ther; 2004 Dec; 9(6):979-85. PubMed ID: 15651756
[TBL] [Abstract][Full Text] [Related]
16. High rebound of plasma and cellular HIV load after discontinuation of triple combination therapy.
Jubault V; Burgard M; Le Corfec E; Costagliola D; Rouzioux C; Viard JP
AIDS; 1998 Dec; 12(17):2358-9. PubMed ID: 9863885
[No Abstract] [Full Text] [Related]
17. Update on antivirals.
Proj Inf Perspect; 1997 Nov; (23):8-11. PubMed ID: 11365381
[TBL] [Abstract][Full Text] [Related]
18. DMP 266 on the horizon.
Vazquez E
Posit Aware; 1997; 8(5):25. PubMed ID: 11364636
[TBL] [Abstract][Full Text] [Related]
19. Saquinavir plus ritonavir reduce viral load by 99.9 percent.
Vazquez E
Posit Aware; 1996; 7(6):8-9. PubMed ID: 11363983
[TBL] [Abstract][Full Text] [Related]
20. Indinavir/ritonavir-based therapy in HIV-1-infected antiretroviral therapy-naive patients: comparison of 800/100 mg and 400/100 mg twice daily.
Konopnicki D; De Wit S; Poll B; Crommentuyn K; Huitema A; Clumeck N
HIV Med; 2005 Jan; 6(1):1-6. PubMed ID: 15670245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
